FHIRsmith: MedicationRequest/MedicationRequest-mii-exa-mtb-medication-request-mirvetuximab.json

FHIR IG analytics

Package	de.medizininformatikinitiative.kerndatensatz.mtb
Resource Type	MedicationRequest
Id	MedicationRequest-mii-exa-mtb-medication-request-mirvetuximab.json
FHIR Version	R4

Resources that use this resource

No resources found

Resources that this resource uses

No resources found

Narrative

Note: links and images are rebased to the (stated) source

English

Generated Narrative: MedicationRequest mii-exa-mtb-medication-request-mirvetuximab

Profile: MII PR MTB Therapieempfehlung Systemische Therapie version: 2027.0.0-ballot.1

MII EX MTB Empfehlung Priorität: 1

MII EX MTB Empfehlung Evidenzgraduierung: Predictive value of the biomarker or clinical effectiveness of the corresponding drug in a molecularly stratified cohort was demonstrated in a prospective study or a meta-analysis in the same tumor type.

MII EX MTB Empfehlung Publikation: http://doi.org/10.1200/JCO.2022.40.16_suppl.5512

MII EX MTB Empfehlung Publikation: http://www.ncbi.nlm.nih.gov/pubmed/38055253

status: Completed

intent: Proposal

medication: MIRVETUXIMAB SORAVTANSINE

subject: Kim Musterperson (no stated gender), DoB: 1956-03-14

authoredOn: 2023-03-28

reasonReference: Condition Bösartige Neubildung: Peritoneum, nicht näher bezeichnet

basedOn: CarePlan: status = active; intent = plan; category = prätherapeutische Tumorkonferenz (Festlegung der Therapiestrategie); created = 2023-03-28

German

Generated Narrative: MedicationRequest mii-exa-mtb-medication-request-mirvetuximab

Profile: MII PR MTB Therapieempfehlung Systemische Therapie version: 2027.0.0-ballot.1

MII EX MTB Empfehlung Priorität: 1

MII EX MTB Empfehlung Evidenzgraduierung: m1A

MII EX MTB Empfehlung Publikation: http://doi.org/10.1200/JCO.2022.40.16_suppl.5512

MII EX MTB Empfehlung Publikation: http://www.ncbi.nlm.nih.gov/pubmed/38055253

status: Completed

intent: Proposal

medication: MIRVETUXIMAB SORAVTANSINE

subject: Kim Musterperson (no stated gender), DoB: 1956-03-14

authoredOn: 2023-03-28

reasonReference: Condition Bösartige Neubildung: Peritoneum, nicht näher bezeichnet

basedOn: CarePlan: status = active; intent = plan; category = prätherapeutische Tumorkonferenz (Festlegung der Therapiestrategie); created = 2023-03-28

Source1

{
  "resourceType": "MedicationRequest",
  "id": "mii-exa-mtb-medication-request-mirvetuximab",
  "meta": {
    "profile": [
      "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-therapieempfehlung|2027.0.0-ballot.1"
    ]
  },
  "text": {
    "status": "extensions",
    "div": "<!-- snip (see above) -->"
  },
  "extension": [
    {
      "url": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-ex-mtb-empfehlung-prioritaet",
      "valuePositiveInt": 1
    },
    {
      "url": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-ex-mtb-empfehlung-evidenzgraduierung",
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/CodeSystem/mii-cs-mtb-empfehlung-evidenzgrad",
            "code": "m1A"
          }
        ]
      }
    },
    {
      "url": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-ex-mtb-empfehlung-publikation",
      "valueIdentifier": {
        "system": "http://doi.org",
        "value": "10.1200/JCO.2022.40.16_suppl.5512"
      }
    },
    {
      "url": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-ex-mtb-empfehlung-publikation",
      "valueIdentifier": {
        "system": "http://www.ncbi.nlm.nih.gov/pubmed",
        "value": "38055253"
      }
    }
  ],
  "status": "completed",
  "intent": "proposal",
  "medicationCodeableConcept": {
    "coding": [
      {
        "system": "http://fdasis.nlm.nih.gov",
        "code": "98DE7VN88D",
        "display": "MIRVETUXIMAB SORAVTANSINE"
      },
      {
        "system": "http://fhir.de/CodeSystem/bfarm/atc",
        "version": "2025",
        "code": "L01FX26",
        "display": "Mirvetuximab soravtansin"
      },
      {
        "system": "http://fhir.de/CodeSystem/bfarm/atc",
        "version": "2025",
        "code": "L01FX",
        "display": "Andere monoklonale Antikörper und Antikörper-Wirkstoff-Konjugate"
      }
    ]
  },
  "subject": {
    "reference": "Patient/PatientKimMusterperson"
  },
  "authoredOn": "2023-03-28",
  "reasonReference": [
    {
      "reference": "Condition/PatientKimMusterperson-PrimaryDiagnosis-2"
    }
  ],
  "basedOn": [
    {
      "reference": "CarePlan/mii-exa-mtb-kim-musterperson-therapieplan"
    }
  ]
}